doxercalciferol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| Vitamin D analogues/derivatives | 957 | 54573-75-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
decrease of bone density caused by prednisolone was prevented by above cpd; decreases number of osteoclast areas in normal rats; RN given refers to (1alpha,3beta,5Z,7E,22E)-isomer
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| June 9, 1999 | FDA | GENZYME CORP |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug hypersensitivity | 185.77 | 32.78 | 103 | 1306 | 310584 | 63177029 |
| Peritonitis bacterial | 69.17 | 32.78 | 17 | 1392 | 4862 | 63482751 |
| Pruritus | 63.66 | 32.78 | 57 | 1352 | 361396 | 63126217 |
| Dyspnoea | 50.41 | 32.78 | 67 | 1342 | 661246 | 62826367 |
| Blood parathyroid hormone abnormal | 43.53 | 32.78 | 7 | 1402 | 225 | 63487388 |
| Vomiting | 41.45 | 32.78 | 56 | 1353 | 559561 | 62928052 |
| Unresponsive to stimuli | 40.05 | 32.78 | 18 | 1391 | 33798 | 63453815 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug hypersensitivity | 149.92 | 33.32 | 68 | 1214 | 80461 | 34875188 |
| Pruritus | 60.08 | 33.32 | 46 | 1236 | 141935 | 34813714 |
| Unresponsive to stimuli | 46.95 | 33.32 | 22 | 1260 | 27547 | 34928102 |
| Dyspnoea | 39.80 | 33.32 | 58 | 1224 | 376724 | 34578925 |
| Flushing | 37.78 | 33.32 | 20 | 1262 | 32400 | 34923249 |
| Blood parathyroid hormone increased | 36.88 | 33.32 | 9 | 1273 | 1505 | 34954144 |
| Blood parathyroid hormone abnormal | 35.53 | 33.32 | 6 | 1276 | 156 | 34955493 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug hypersensitivity | 331.25 | 30.67 | 169 | 2379 | 298747 | 79443093 |
| Pruritus | 104.70 | 30.67 | 92 | 2456 | 394556 | 79347284 |
| Peritonitis bacterial | 89.96 | 30.67 | 26 | 2522 | 9541 | 79732299 |
| Unresponsive to stimuli | 83.39 | 30.67 | 39 | 2509 | 55749 | 79686091 |
| Dyspnoea | 63.34 | 30.67 | 104 | 2444 | 856921 | 78884919 |
| Peritoneal dialysis complication | 59.28 | 30.67 | 14 | 2534 | 2340 | 79739500 |
| Vomiting | 52.03 | 30.67 | 83 | 2465 | 665745 | 79076095 |
| Blood parathyroid hormone abnormal | 50.62 | 30.67 | 9 | 2539 | 366 | 79741474 |
| Flushing | 48.71 | 30.67 | 32 | 2516 | 88236 | 79653604 |
| Blood parathyroid hormone increased | 44.44 | 30.67 | 12 | 2536 | 3433 | 79738407 |
| Feeling hot | 38.77 | 30.67 | 24 | 2524 | 59710 | 79682130 |
| Nephrogenic systemic fibrosis | 33.48 | 30.67 | 11 | 2537 | 6149 | 79735691 |
| Nausea | 33.06 | 30.67 | 85 | 2463 | 957111 | 78784729 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | H05BX03 | SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS CALCIUM HOMEOSTASIS ANTI-PARATHYROID AGENTS Other anti-parathyroid agents |
| FDA CS | M0007651 | Ergocalciferols |
| CHEBI has role | CHEBI:50188 | provitamins |
| CHEBI has role | CHEBI:50646 | antiosteoporotic |
| CHEBI has role | CHEBI:71212 | prohormones |
| MeSH PA | D050071 | Bone Density Conservation Agents |
| MeSH PA | D018977 | Micronutrients |
| MeSH PA | D014815 | Vitamins |
| FDA EPC | N0000175907 | Vitamin D2 Analog |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis | indication | ||
| Hyperparathyroidism Secondary to Chronic Renal Failure | off-label use | ||
| Hyperphosphatemia | contraindication | 20165001 | DOID:0050459 |
| Hypervitaminosis D | contraindication | 27712000 | DOID:9971 |
| Hypoparathyroidism | contraindication | 36976004 | DOID:11199 |
| Hypercalcemia | contraindication | 66931009 | DOID:12678 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 13.7 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Vitamin D3 receptor | Nuclear hormone receptor | AGONIST | UNKNOWN | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4021201 | VUID |
| N0000179007 | NUI |
| D01009 | KEGG_DRUG |
| 4021201 | VANDF |
| C0043668 | UMLSCUI |
| CHEBI:4712 | CHEBI |
| V2H | PDB_CHEM_ID |
| CHEMBL1200810 | ChEMBL_ID |
| DB06410 | DRUGBANK_ID |
| C042533 | MESH_SUPPLEMENTAL_RECORD_UI |
| 5281107 | PUBCHEM_CID |
| 2790 | IUPHAR_LIGAND_ID |
| 7878 | INN_ID |
| 3DIZ9LF5Y9 | UNII |
| 11516 | RXNORM |
| 211288 | MMSL |
| 30992 | MMSL |
| 8230 | MMSL |
| d04435 | MMSL |
| 007891 | NDDF |
| 116094003 | SNOMEDCT_US |
| 126234006 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Doxercalciferol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0338 | CAPSULE | 0.50 ug | ORAL | ANDA | 24 sections |
| Doxercalciferol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0339 | CAPSULE | 2.50 ug | ORAL | ANDA | 24 sections |
| Doxercalciferol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0388 | CAPSULE | 1 ug | ORAL | ANDA | 24 sections |
| DOXERCALCIFEROL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-1330 | INJECTION, SOLUTION | 2 ug | INTRAVENOUS | NDA | 26 sections |
| DOXERCALCIFEROL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-1331 | INJECTION, SOLUTION | 2 ug | INTRAVENOUS | NDA | 26 sections |
| Doxercalciferol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6154 | INJECTION | 2 ug | INTRAVENOUS | ANDA | 23 sections |
| Doxercalciferol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0955-1720 | CAPSULE | 0.50 ug | ORAL | NDA authorized generic | 26 sections |
| Doxercalciferol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0955-1721 | CAPSULE | 1 ug | ORAL | NDA authorized generic | 26 sections |
| Doxercalciferol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0955-1722 | CAPSULE | 2.50 ug | ORAL | NDA authorized generic | 26 sections |
| Doxercalciferol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-987 | INJECTION, SOLUTION | 2 ug | INTRAVENOUS | ANDA | 25 sections |
| Doxercalciferol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-988 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | ANDA | 25 sections |
| Doxercalciferol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-538 | CAPSULE | 0.50 ug | ORAL | ANDA | 22 sections |
| Doxercalciferol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-539 | CAPSULE | 1 ug | ORAL | ANDA | 22 sections |
| Doxercalciferol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-540 | CAPSULE | 2.50 ug | ORAL | ANDA | 22 sections |
| DOXERCALCIFEROL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-850 | INJECTION | 4 ug | INTRAVENOUS | ANDA | 24 sections |
| Doxercalciferol | Human Prescription Drug Label | 1 | 55150-357 | INJECTION, SOLUTION | 2 ug | INTRAVENOUS | ANDA | 24 sections |
| Doxercalciferol | Human Prescription Drug Label | 1 | 55150-358 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | ANDA | 24 sections |
| Doxercalciferol | Human Prescription Drug Label | 1 | 55150-359 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | ANDA | 24 sections |
| Hectorol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 58468-0123 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | NDA | 26 sections |
| Hectorol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 58468-0123 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | NDA | 26 sections |
| Hectorol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 58468-0126 | INJECTION, SOLUTION | 2 ug | INTRAVENOUS | NDA | 26 sections |
| Hectorol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 58468-0126 | INJECTION, SOLUTION | 2 ug | INTRAVENOUS | NDA | 26 sections |
| Hectorol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 58468-0127 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | NDA | 26 sections |
| Hectorol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 58468-0127 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | NDA | 26 sections |
| Doxercalciferol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62135-450 | CAPSULE | 0.50 ug | ORAL | ANDA | 17 sections |
| Doxercalciferol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62135-451 | CAPSULE | 1 ug | ORAL | ANDA | 17 sections |
| Doxercalciferol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62135-452 | CAPSULE | 2.50 ug | ORAL | ANDA | 17 sections |
| Doxercalciferol | Human Prescription Drug Label | 1 | 62332-690 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | ANDA | 23 sections |
| Doxercalciferol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64980-228 | CAPSULE | 0.50 ug | ORAL | ANDA | 30 sections |
| Doxercalciferol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64980-228 | CAPSULE | 0.50 ug | ORAL | ANDA | 30 sections |